 |
| BIOSPECIFICS TECHNOLOGIES CORP. |
| BioSpecifics Technolgies Corp.
Condensed Balance Sheets
ASSETS |
July 31,1999
(unaudited)
|
January
31,1999
|
| Cash, cash equivalents, and marketable securities |
$6,500,000
|
$7,190,000
|
| Other current assets |
3,854,000
|
3,249,000
|
| Total current assets |
10,354,000
|
10,439,000
|
| PP&E and other assets |
985,000
|
937,000
|
| Total Assets |
11,339,000
|
11,376,000
|
| |
|
|
| LIABILITIES |
|
|
| Current liabilities |
1,646,000
|
1,446,000
|
| Other liabilities |
265,000
|
261,000
|
| Stockholders' equity - net |
9,428,000
|
9,669,00
|
| Total Liabilities & Stockholders Equity |
$11,339,000
|
$11,376,000
|
| |
|
|
| Shares outstanding |
4,530,000
|
4,580,000
|
|
|
BioSpecifics
Condensed
Statements
of Income |
(Unaudited)
Three mos.
ended
|
(Unaudited)
|
(Unaudited)
|
(Unaudited)
Six mos.
ended
July 31,
1998 |
| Sales, net |
$1,061,000
|
$1,065,000
|
$1,744,000
|
$2,288,000
|
| Royalties & license fees |
675,000
|
960,000
|
1,271,000
|
1,444,000
|
| Revenues |
1,736,000
|
2,025,000
|
3,015,000
|
3,732,000
|
| |
|
|
|
|
| Cost of sales |
605,000
|
553,000
|
1,013,000
|
1,100,000
|
| SG&A |
821,000
|
479,000
|
1,467,000
|
909,000
|
| R&D |
467,000
|
570,000
|
973,000
|
991,000
|
| Total operating costs |
1,893,000
|
1,602,000
|
3,453,000
|
3,000,000
|
| |
|
|
|
|
Income (loss)
from operations |
(157,000)
|
423,000
|
(438,000)
|
732,000
|
| Other income - net |
80,500
|
52,000
|
124,500
|
108,000
|
Income (loss) before
income tax |
(76,500)
|
475,000
|
(313,500)
|
840,000
|
Income tax expense
(benefit) |
(150,000)
|
126,000
|
(250,000)
|
262,000
|
| Net income (loss) |
$73,500
|
$349,000
|
$(63,500)
|
$578,000
|
| EPS |
$0.02
|
$0.07
|
$(0.01)
|
$0.12
|
| |
|
|
|
|
| Diluted shares |
4,538,000
|
4,885,000
|
4,551,000
|
4,903,000
|
|
